by kshughes | Mar 3, 2016 | Genetic Testing, Guidelines, Lifetime Risk, MRI, Population Level Risk, Tyrer Cuzick
Risk is defined in 2 ways: Risk of mutation (If risk of mutation is 10% or greater consider genetic testing) Risk of breast cancer (If lifetime risk of breast cancer is 20% or greater get an MRI) 4% of your population getting mammography will need genetic testing For...
by kshughes | Mar 3, 2016 | BRCAPRO, Genetic Testing, Lifetime Risk, Models, MRI, Population Level Risk, Tyrer Cuzick
In a breast imaging population, about 1 in 25 will be eligible for genetic testing. If you are only using BRCAPRO, only 1 in 200 will need an MRI. Use Tyrer Cuzick 7, and you will see that about 15% will need an MRI....
by kshughes | Mar 3, 2016 | Genetic Testing
If you test a group of patients with a 10% or greater risk of mutation, about 17% will be mutation carriers. If you test patients based on the NCCN guidelines
by kshughes | Mar 3, 2016 | BRCAPRO, Claus, Gail, Genetic Testing, Guidelines, Lifetime Risk, MRI, Population Level Risk, Tyrer Cuzick
If you use Tyrer Cuzick7, about 15% will need an MRI. If you use Claus, about 0.9% will need an MRI. If you use BRCAPRO, about 0.5% will need an MRI. [ASCO_2014_NCCNB_BRCAPRO_TyrerCuzickRiskMutationsLifetimeRisk]
by kshughes | Mar 3, 2016 | Genetic Testing, Guidelines, Hughes RiskApps, Hughes RiskApps Express, MRI, Population Level Risk
Although the survey asks patients about their atypia, LCIS status and past genetic test results, the self-reported response is NOT accepted as true until verified by the user. Risk calculations are not run nor presented in the survey summary until the clinician or...
by kshughes | Mar 3, 2016 | Genetic Testing, Hughes RiskApps, Hughes RiskApps Express
There is no mutation listed in the pedigree, just significance. Ideally the mutation variant should be entered. The correct answer is: “Test patient (ASO)” ASO means Allele-Specific Oligonucleotide (ASO), which is the term we used for family specific mutation...
